Collection of Saliva and/ or Peripheral Blood From Healthy Volunteers for Research
NCT ID: NCT01851382
Last Updated: 2022-07-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
29 participants
OBSERVATIONAL
2013-05-15
2015-02-12
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
\- Researchers often collect samples from healthy volunteers to further their research. These samples can help better understand serious side effects and complications of transplant treatments in patients. This study will collect saliva samples from healthy volunteers.
Objectives:
\- To collect saliva and blood samples from healthy volunteers for research studies.
Eligibility:
\- Healthy men ages 30-70 years for Phase I of the study.
Design:
* Participants will be screened with a medical history questionnaire. They will also have a brief oral exam to check for any mouth infection.
* Participants will provide a saliva sample. The collection process will take about 5 minutes.
* No treatment will be given as part of this study.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Salivary Evaluation in Healthy Volunteers
NCT00001390
Characterization of Diseases With Salivary Gland Involvement
NCT02327884
Occurrence of Selected Vitamins in Saliva and Blood
NCT02592148
Using Saliva Stimulation to Immediately Improve Heart Failure Inpatient's Thirst Sensation
NCT05325983
Potential of Transplanted Stem Cells to Mature Into Salivary Gland and Cheek Cells
NCT00023491
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Chronic graft-versus-host disease (cGVHD) is a severe immunological complication that occurs after allogeneic hematopoietic stem cell transplantation (HSCT). Although oral cGVHD occurs in \>25% of cGVHD patients and leads to decreased quality of life, its etiology is poorly understood.
* The primary objective of the present protocol is to enroll normal volunteers who will contribute a saliva and/or blood sample in order to compare its characteristics with those of patients with and without chronic GVHD after allogeneic HSCT. The normal control saliva and blood samples will provide a standard of comparison for patient saliva and blood samples from ongoing NCI cGVHD related protocols.
Objective:
-To collect approximately 5 ml of saliva and/or 18 cc peripheral blood from healthy volunteers as needed to support research activities.
Eligibility:
* Healthy individuals (including employees) all racial/ethnic groups, aged 18 years or older.
* Volunteers must be willing to undergo saliva and peripheral blood collection.
* No active illnesses, immunodeficiency, history of opportunistic infection, autoimmune disease, immunosuppressive medications or prior organ, bone marrow or peripheral blood stem cell transplant.
* Ability of subject to understand and provide written informed consent.
* Phase I of the study will be restricted to males, age 30-70 years
Design:
* Healthy volunteers will be offered the opportunity to participate in this protocol.
* A basic clinical dental assessment will be done.
* Saliva samples will be collected from the consenting subject.
* Peripheral blood samples may be collected from the consenting subject at the same visit.
* Protein assays will be performed on the collected saliva and blood samples.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort 1
Healthy volunteers.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age 18 years and older, with possible restriction for age-matching to patient samples.
* Ability of subject to understand and provide written informed consent
* Subjects must participate fully and be willing to comply with the procedures of the protocol
* Phase I of the study will be restricted to males, age 30-70 years.
Exclusion Criteria
* Prior organ, bone marrow or peripheral blood stem cell transplant
* Acute dental infection
18 Years
99 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Steven Z Pavletic, M.D.
Role: PRINCIPAL_INVESTIGATOR
National Cancer Institute (NCI)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Mays JW, Fassil H, Edwards DA, Pavletic SZ, Bassim CW. Oral chronic graft-versus-host disease: current pathogenesis, therapy, and research. Oral Dis. 2013 May;19(4):327-46. doi: 10.1111/odi.12028. Epub 2012 Oct 28.
Bassim CW, Ambatipudi KS, Mays JW, Edwards DA, Swatkoski S, Fassil H, Baird K, Gucek M, Melvin JE, Pavletic SZ. Quantitative salivary proteomic differences in oral chronic graft-versus-host disease. J Clin Immunol. 2012 Dec;32(6):1390-9. doi: 10.1007/s10875-012-9738-4. Epub 2012 Jul 18.
Related Links
Access external resources that provide additional context or updates about the study.
NIH Clinical Center Detailed Web Page
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
13-C-0128
Identifier Type: -
Identifier Source: secondary_id
130128
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.